Johnson & Johnson Innovation – JJDC, Inc.

Investing in and supporting the
global entrepreneurial community

Learn more

About us


Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is focused on growing companies, not just investments. As the strategic venture capital arm of Johnson & Johnson, we pursue opportunities to solve critical healthcare needs. Our partners benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation. 


JJDC 2018 Newsletter

2018 marks an important milestone for JJDC as we celebrate our 45th anniversary as strategic investors for the Johnson & Johnson Family of Companies.

Click here to view newsletter

JJDC finds transformative ideas and helps them mature into real solutions for today’s patients. 

Guided by a clear, consistent investment strategy aligned with scientific goals, JJDC works hand-in-hand with partners to navigate the path to creating breakthrough health innovations. 

We invest across sectors—pharmaceuticals, medical devices and consumer healthcare—and at all stages, from seed-level startups to Series B and beyond.  

All of our portfolio companies receive the same unwavering commitment. We take a long-term approach, deploying the full capabilities of the Johnson & Johnson family of companies, including discovery, clinical development, regulatory affairs, manufacturing and commercialization. 

Our team includes leaders in the healthcare and technology communities, many with deep R&D experience. This gives us the ability to understand our partners and provide the help they need. 

Every opportunity is unique, with tailored roles and terms that provide the best path to success. 


  • Tom Heyman
    President JJDC
  • Jeanne Bolger
    Jeanne Bolger
    Vice President, Venture Investments
  • Renee Compton Ryan
    Renee Compton Ryan
    Vice President, Venture Investments
  • Maciek Drozdz
    Principal, Venture Investments
  • Stacy Feld
    Vice President of Consumer Venture Investments and External Innovation
  • V. Kadir Kadhiresan, PhD
    V. Kadir Kadhiresan
    Vice President, Venture Investments
  • Ajay Khatri
    Ajay Khatri
    Director, Venture Investments
  • Tamir Meiri JJDC
    Tamir Meiri
    Senior Manager of Venture Investments
  • Vijay Murthy
    Principal, Venture Investments
  • Marian Nakada
    Marian Nakada
    Vice President, Venture Investments
  • Asish K. Xavier
    Vice President, Venture Investments
  • Zeev Zehavi
    Vice President, Venture Investments


We’re positively impacting human health through innovation. To do this, we identify the best opportunities across all sectors and allow innovators to leverage Johnson & Johnson’s many resources.

We’ve Been There Before

Our highly experienced team hails from throughout the healthcare and technology venture communities, many of us bringing deep R&D experience in addition to investment acumen. Just like you, we are entrepreneurs, scientists and studied risk-takers. Our team’s unique vantage point gives us an exceptional ability to understand the challenges and provide the right kind of help at the right time.    

Investing With Impact 

We have dedicated teams focused on investing at all stages of innovation, and across all four sectors: pharmaceuticals, medical devices, consumer health and global public health. We seek innovations with potential to make a transformational impact in the health and lives of people around the globe. 

If your early-stage company is looking to advance a program that is pre-proof of concept in humans, connect with one of our Johnson & Johnson Innovation Centers, located around the globe in the life science hot spots of Asia Pacific, Boston, California and London.

Each Investment Is Unique

At JJDC, there’s no such thing as a one-size-fits-all approach. We understand that each idea is unique, requiring an equally distinct investment strategy. We customize every deal to the opportunity, ranging from Seed and Series A investments in the earliest-stage startups to Series B investments and beyond in more mature companies. We also make private investments in public equity.

Creating Thriving Enterprises

For more than 40 years, JJDC has made investments in hundreds of innovative companies across pharmaceuticals, medical devices and consumer healthcare. Once we invest, we’re committed to you. We believe in value-add investing, playing an active role in providing strategic direction and enabling access to internal experts across the Johnson & Johnson Family of Companies.

Focus Areas

JJDC is seeks ideas that align with our business priorities in our Pharmaceuticals, Consumer and Medical Devices sectors. In each sector, we focus on specific therapeutic areas of interest that have the greatest potential to improve the lives of patients and consumers.

CLICK a business area of interest below
  • Consumer
  • Medical Devices
  • Pharmaceuticals
  • Global Public Health
CLICK on a circle to see the areas we are targeting
  • Baby Skin, Mother & Baby
    Baby Care
    Baby Care
  • Healthy Skin, Digital Beauty, Naturals
  • Novel Wound Healing Solutions
    Wound Care
    Wound Care
  • Sustainable Materials
    Feminine Personal Care
    Feminine Personal Care
  • Biofilm Innovation, Whitening Technologies
    Oral Care
    Oral Care
  • Pain Care, Digestive Health, Allergy Prevention & Solutions, Smoking Cessation, Cough & Colds


No results found


Portfolio Company News

  • Provention Bio Announces Closing of Upsized Initial Public Offering

    Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced today the closing of its initial public offering of shares of its common stock at a public offering price of $4.00 per share on July 19, 2018. The gross proceeds from the offering were approximately $63.9 million, before deducting underwriting discounts and commissions and other offering expenses.

    Read More
  • Asceneuron's Tau Modifier ASN120290 Receives Orphan Drug Designation for Progressive Supranuclear Palsy From the FDA

    Asceneuron SA, an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ASN120290 for the treatment of progressive supranuclear palsy (PSP), a rapidly progressing rare neurodegenerative disorder.

    Read More
  • Cue Health Completes $45MM Series B Financing

    Cue Health Inc. (“Cue”), a healthcare technology company developing a range of diagnostic products for professionals and consumers, announced today it has raised over $45MM in Series B financing. The financing will be used to complete development and fund the initial set of FDA 510(k) clinical studies for Cue’s first set of diagnostic products

    Read More
  • Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression

    Navitor Pharmaceuticals, Inc., a biopharmaceutical company targeting the mTORC1 pathway to develop novel therapeutics that help patients live longer and healthier lives, announced today the initiation of a Phase 1 clinical study with its lead pipeline candidate, NV-5138, for treatment-resistant depression (TRD). NV-5138 is a novel small molecule that directly activates mTORC1, a master cellular regulator that has recently been shown to be a central signaling pathway required for the efficacy of several rapid acting antidepressants.

    Read More
  • Dreem Announces $35 Million Financing from lead investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Bpifrance to Accelerate Innovations in the Field of Sleep Science

    Dreem, a neurotechnology company, today announced the closing of a new round of funding, raising $35 million USD to rapidly accelerate product development, invest in strategic research and development, and advance the future of sleep technology. Last year, Dreem introduced a comprehensive solution to address a suite of sleep problems and enhance the quality of rest during the night.

    Read More



Make the Connection

We look forward to our first discussion.  If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.